bluebird, Medigene partner to develop TCRs

bluebird bio Inc. (NASDAQ:BLUE) and Medigene AG (Xetra:MDG1) partnered to develop T cell receptor immunotherapies against four undisclosed targets to treat cancer.

The companies intend to collaborate on preclinical development. Medigene will be responsible for producing TCRs and bluebird will be responsible for clinical development and commercialization, and will have exclusive rights to any candidates produced in the partnership. ...